Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for Tandem Diabetes Care (TNDM) over the last 13 years, with Q3 2025 value amounting to $4.2 million.

  • Tandem Diabetes Care's Free Cash Flow fell 8063.14% to $4.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$25.1 million, marking a year-over-year decrease of 6673.3%. This contributed to the annual value of $5.0 million for FY2024, which is 10852.01% up from last year.
  • According to the latest figures from Q3 2025, Tandem Diabetes Care's Free Cash Flow is $4.2 million, which was down 8063.14% from -$14.5 million recorded in Q2 2025.
  • Over the past 5 years, Tandem Diabetes Care's Free Cash Flow peaked at $31.0 million during Q3 2021, and registered a low of -$27.2 million during Q1 2023.
  • Moreover, its 5-year median value for Free Cash Flow was $193000.0 (2022), whereas its average is $1.4 million.
  • Per our database at Business Quant, Tandem Diabetes Care's Free Cash Flow crashed by 653264.25% in 2023 and then soared by 50299.35% in 2024.
  • Over the past 5 years, Tandem Diabetes Care's Free Cash Flow (Quarter) stood at $13.9 million in 2021, then crashed by 98.61% to $193000.0 in 2022, then crashed by 6532.64% to -$12.4 million in 2023, then soared by 161.6% to $7.6 million in 2024, then crashed by 45.45% to $4.2 million in 2025.
  • Its Free Cash Flow was $4.2 million in Q3 2025, compared to -$14.5 million in Q2 2025 and -$22.5 million in Q1 2025.